The Emerging Role of Biotechnological Drugs in the Treatment of Gout
Open Access
- 16 April 2014
- journal article
- review article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2014, 1-9
Abstract
One of the most important therapeutic advances obtained in the field of rheumatology is the availability of the so-called bio(techno)logical drugs, which have deeply changed treatment perspectives in diseases such as rheumatoid arthritis and ankylosing spondylitis. According to the steadily increasing attention on gout, due to well-established prognostic and epidemiology implications, in the last 5 years, the same change of perspective has been observed also for this disease. In fact, several bio(techno)logical agents have been investigated both for the management of the articular gout symptoms, targeting mainly interleukin-1β, as well as urate-lowering therapies such as recombinant uricases. Among the IL-1βinhibitors, the majority of studies involve drugs such as anakinra, canakinumab, and rilonacept, but other compounds are under development. Moreover, other potential targets have been suggested, as, for example, the TNF alpha and IL-6, even if data obtained are less robust than those of IL-1βinhibitors. Regarding urate-lowering therapies, the recombinant uricases pegloticase and rasburicase clearly showed their effectiveness in gout patients. Also in this case, new compounds are under development. The aim of this review is to focus on the various aspects of different bio(techno)logical drugs in gouty patients.Keywords
This publication has 99 references indexed in Scilit:
- Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]The American Journal of Cardiology, 2013
- Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparatorArthritis Research & Therapy, 2013
- Bone destruction by receptor activator of nuclear factor κB ligand-expressing T cells in chronic gouty arthritisArthritis Research & Therapy, 2011
- Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised studyAnnals of the Rheumatic Diseases, 2011
- Gout treatment and comorbidities: a retrospective cohort study in a large US managed care populationBMC Musculoskeletal Disorders, 2011
- Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging studyArthritis Research & Therapy, 2011
- Contemporary epidemiology of gout in the UK general populationArthritis Research & Therapy, 2011
- Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinraAnnals of the Rheumatic Diseases, 2007
- A pilot study of IL-1 inhibition by anakinra in acute goutArthritis Research & Therapy, 2007
- EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)Annals of the Rheumatic Diseases, 2006